Advertisement
PRMA Consulting - Integrated Evidence Generation 2.0

C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!

Breakthrough Gedatolisib Therapy Discovered for the Treatment of Metastatic Breast Cancer

Celcuity Inc discovered Gedatolisib new therapy for the treatment of HR+/HER2- Metastatic Breast Cancer.

Gedatolisib, the first-in-class pan-PI3K/mTOR inhibitor, is applicable for patients progressed with CDK4/6 therapy and a non-steroidal aromatase inhibitor.

Gedatolisib is a potent, reversible dual inhibitor selectively targeting all Class I PI3K isoforms and mTOR. Moreover, mechanism action of Gedatolisib and pharmacokinetic properties can be highly varied from currently available otherinvestigational therapies that target PI3K or mTOR alone or together.

Class 1 PI3K isoforms and mTOR limits the potential growth of drug resistance when compared to that of isoform specific PI3K or mTOR specific inhibitors.

In Phase 1b clinical trial, gedatolisib evaluated manageable side effects in combination with palbociclib and endocrine therapy in patients with HR+/HER2- advanced breast cancer.In addition, phase 3 trial evaluating gedatolisib in patients with HR+/HER2- advanced breast cancer in 2022.

U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEA SGS - ADVANCED ANALYTICS Adare Pharma Solutions - Pediatric Formulation Solutions Thermo Fisher Scientific - 60th year celebration of The Gibco brand Thermo Fisher Scientific - LC-MS biopharmaceutical applications CPC - The Future of Aseptic Connections in Cell and Gene Therapies CPHI PMEC China - Virtual Expo Connect ThermoFisher - Accekerate therapeutic development